Literature DB >> 19329698

Clinical features of hepatic myelopathy in patients with chronic liver disease.

Y H Yin1, Z J Ma, Y H Guan, Y D Ren, Z L Zhang.   

Abstract

AIM: To determine the clinical features of hepatic myelopathy (HM), a rare condition associated with chronic liver disease (CLD), in patients in the city of Harbin, China.
METHODS: The medical files of 13 patients with HM were selected from 500 randomly chosen files of CLD patients registered in four Harbin hospitals. General information on all cases was summarised and clinical features were compared between HM positive patients (HM group) and HM negative CLD patients (control group). Detailed analysis of the clinical characteristics of HM positive patients was undertaken.
RESULTS: The patients in the HM group ranged in age from 41-50 years, which did not differ significantly from the control group. However, the sex ratio in the HM group (12 males/1 female) was significantly higher (p<0.05) than in the control group (342 males/145 females).The most frequent underlying aetiology was post type B hepatitis (12 cases). All cases in the HM group had a history of relapsing hepatic encephalopathy (HE) before or after HM onset, and showed electroencephalographic (EEG) abnormalities; however, the results of spinal cord magnetic resonance imaging were negative, and cerebrospinal fluid analysis findings were normal. Except for clinical manifestations of bilateral lower limb spastic paralysis, the two groups did not differ significantly in regard to other symptoms or signs. Hypoproteinaemia (positive predictive value (PPV) 5.69%, negative predictive value (NPV) 99.65%), blood ammonia elevation (PPV 5.29%, NPV, 99.32%) and abnormal EEG (PPV 5.00%, NPV 100.00%) were sensitive and specific for HM diagnosis.
CONCLUSION: In Harbin, HM is found mainly among middle aged men with CLD caused by viral hepatitis and accompanied by relapsing onset of HE. Bilateral lower limb spastic paralysis with hypoproteinaemia, blood ammonia elevation and/or abnormal EEG are significant diagnostic indicators of HM.

Entities:  

Mesh:

Year:  2009        PMID: 19329698     DOI: 10.1136/pgmj.2007.067371

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  3 in total

1.  Portosystemic myelopathy: a rare neurological presentation of portosystemic shunts.

Authors:  Prasanna K S Rao; Keyur A Sheth; Raghunandan Nadig; Mallikarjun Patil; Adarsh K Channagiri
Journal:  J Clin Exp Hepatol       Date:  2012-10-22

Review 2.  Spinal cord involvement in patients with cirrhosis.

Authors:  Raffaele Nardone; Yvonne Höller; Monica Storti; Piergiorgio Lochner; Frediano Tezzon; Stefan Golaszewski; Francesco Brigo; Eugen Trinka
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

3.  Benefits of Early Treatment for Patients with Hepatic Myelopathy Secondary to TIPS: A Retrospective Study in Northern China.

Authors:  Hongwei Zhao; Zhendong Yue; Lei Wang; Zhenhua Fan; Fuliang He; Xiaoqun Dong; Fuquan Liu
Journal:  Sci Rep       Date:  2018-10-12       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.